Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9078 USD 0.81% Market Closed
Market Cap: 167.5m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nektar Therapeutics
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Total Equity
$48.9m
CAGR 3-Years
-61%
CAGR 5-Years
-50%
CAGR 10-Years
0%
Johnson & Johnson
NYSE:JNJ
Total Equity
$70.2B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Bristol-Myers Squibb Co
NYSE:BMY
Total Equity
$17.1B
CAGR 3-Years
-23%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Pfizer Inc
NYSE:PFE
Total Equity
$87.7B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Total Equity
$44.5B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Total Equity
$14.2B
CAGR 3-Years
22%
CAGR 5-Years
33%
CAGR 10-Years
-2%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
167.5m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Total Equity?
Total Equity
48.9m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Total Equity amounts to 48.9m USD.

What is Nektar Therapeutics's Total Equity growth rate?
Total Equity CAGR 10Y
0%

Over the last year, the Total Equity growth was -69%. The average annual Total Equity growth rates for Nektar Therapeutics have been -61% over the past three years , -50% over the past five years .

Back to Top